Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Income from Continuing Operations (2023 - 2026)

Compass Therapeutics' Income from Continuing Operations history spans 4 years, with the latest figure at 20299000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 22.04% to 20299000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 75172000.0, a 28.45% decrease, with the full-year FY2025 number at 72839000.0, down 28.63% from a year prior.
  • Income from Continuing Operations hit 20299000.0 in Q1 2026 for Compass Therapeutics, down from 17990000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CMPX hit a ceiling of 7837000.0 in Q1 2023 and a floor of 21066000.0 in Q2 2025.
  • Historically, Income from Continuing Operations has averaged 14382692.31 across 4 years, with a median of 13415000.0 in 2023.
  • The widest YoY moves for Income from Continuing Operations: up 8.54% in 2025, down 61.1% in 2025.
  • Tracing CMPX's Income from Continuing Operations over 4 years: stood at 13415000.0 in 2023, then fell by 23.55% to 16574000.0 in 2024, then fell by 8.54% to 17990000.0 in 2025, then fell by 12.83% to 20299000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for CMPX at 20299000.0 in Q1 2026, 17990000.0 in Q4 2025, and 15817000.0 in Q3 2025.